表紙:小児用ワクチンの世界市場 - シェア・予測 (2022年~2027年) :業界動向、成長、規模、COVID-19の影響、企業分析
市場調査レポート
商品コード
1045915

小児用ワクチンの世界市場 - シェア・予測 (2022年~2027年) :業界動向、成長、規模、COVID-19の影響、企業分析

Pediatric Vaccines Market, Share, Global Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis

出版日: | 発行: Renub Research | ページ情報: 英文 150 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
小児用ワクチンの世界市場 - シェア・予測 (2022年~2027年) :業界動向、成長、規模、COVID-19の影響、企業分析
出版日: 2022年01月01日
発行: Renub Research
ページ情報: 英文 150 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の小児用ワクチンの市場規模は、2021年の478億米ドルから、2027年までに620億米ドルに達し、2021年~2027年のCAGRで4.4%の成長が予測されています。世界の小児用ワクチン市場は堅調で、莫大な可能性に到達することに成功しています。

当レポートでは、世界の小児用ワクチン市場について調査分析し、業界動向、成長、規模、COVID-19の影響、主要企業などについて、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 成長促進要因
  • 課題

第5章 小児用ワクチン市場

第6章 小児用ワクチン接種回数

第7章 市場・接種回数のシェア - 小児用ワクチン分析

  • 小児用ワクチン市場シェア
  • 小児用ワクチン接種人数シェア
  • 地域別の市場シェア

第8章 疾患別 - 小児用ワクチン市場

  • インフルエンザ
  • MMR (麻疹、おたふく風邪、風疹)
  • 肺炎球菌
  • 髄膜炎菌
  • 肝炎
  • DTaP
  • Hib (インフルエンザ菌b型)
  • 混合ワクチン
  • ポリオ
  • ロタウイルス
  • 水痘

第9章 疾患別 - 小児用ワクチン接種人数

  • インフルエンザ
  • MMR
  • 肺炎球菌
  • 髄膜炎菌
  • 肝炎
  • DTaP
  • Hib (インフルエンザ菌b型)
  • 混合ワクチン
  • ポリオ
  • ロタウイルス
  • 水痘

第10章 地域別 - 小児用ワクチン市場・接種回数

  • 北米
    • 市場
    • 接種回数
  • 欧州
    • 市場
    • 接種回数
  • アジア太平洋地域
    • 市場
    • 接種回数
  • ラテンアメリカ
    • 市場
    • 接種回数
  • 中東・アフリカ
    • 市場
    • 接種回数

第11章 ワクチン業界におけるM&A

第12章 ワクチンと規制当局の介入

  • 品質と安全性の基準
  • ワクチンの資金調達

第13章 ワクチン - 製品とパイプライン

  • GSKワクチン製品パイプライン
  • Merckワクチン製品パイプライン
  • Sanofiワクチン製品パイプライン
  • Pfizerワクチン製品パイプライン

第14章 ポーターのファイブフォース

  • 概要
  • 買い手の交渉力
  • 供給業者の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 企業分析

  • GlaxoSmithKline, plc.
  • Merck & Co.
  • Sanofi Pasteur's
  • Pfizer, Inc.'s
  • CSL Limited
図表

List of Figures

  • Figure-01: Global Pediatric (Infant) Vaccines Market (Million US$), 2016 - 2021
  • Figure-02: Global - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2022 - 2027
  • Figure-03: Global - Pediatric (Infant) Vaccines Number (Million), 2016 - 2021
  • Figure-04: Global - Forecast for Pediatric (Infant) Vaccines Number (Million), 2022 - 2027
  • Figure-05: Disease wise - Influenza Market (Million US$), 2016 - 2021
  • Figure-06: Disease wise - Forecast for Influenza Market (Million US$), 2022 - 2027
  • Figure-07: Disease wise - MMR (Measles, Mumps, and Rubella Vaccine) Market (Million US$), 2016 - 2021
  • Figure-08: Disease wise - Forecast for MMR (Measles, Mumps, and Rubella Vaccine) Market (Million US$), 2022 - 2027
  • Figure-09: Disease wise - Pneumococcal Market (Million US$), 2016 - 2021
  • Figure-10: Disease wise - Forecast for Pneumococcal Market (Million US$), 2022 - 2027
  • Figure-11: Disease wise - Meningococcal Market (Million US$), 2016 - 2021
  • Figure-12: Disease wise - Forecast for Meningococcal Market (Million US$), 2022 - 2027
  • Figure-13: Disease wise - Hepatitis Market (Million US$), 2016 - 2021
  • Figure-14: Disease wise - Forecast for Hepatitis Market (Million US$), 2022 - 2027
  • Figure-15: Disease wise - DTaP Market (Million US$), 2016 - 2021
  • Figure-16: Disease wise - Forecast for DTaP Market (Million US$), 2022 - 2027
  • Figure-17: Disease wise - Haemophilus Influenzae Type B (HIB) Market (Million US$), 2016 - 2021
  • Figure-18: Disease wise - Forecast for Haemophilus Influenzae Type B (HIB) Market (Million US$), 2022 - 2027
  • Figure-19: Disease wise - Combos (Combination) Market (Million US$), 2016 - 2021
  • Figure-20: Disease wise - Forecast for Combos (Combination) Market (Million US$), 2022 - 2027
  • Figure-21: Disease wise - Polio Market (Million US$), 2016 - 2021
  • Figure-22: Disease wise - Forecast for Polio Market (Million US$), 2022 - 2027
  • Figure-23: Disease wise - Rotavirus Market (Million US$), 2016 - 2021
  • Figure-24: Disease wise - Forecast for Rotavirus Market (Million US$), 2022 - 2027
  • Figure-25: Disease wise - Varicella Market (Million US$), 2016 - 2021
  • Figure-26: Disease wise - Forecast for Varicella Market (Million US$), 2022 - 2027
  • Figure-27: Disease wise - Influenza Number (Million), 2016 - 2021
  • Figure-28: Disease wise - Forecast for Influenza Number (Million), 2022 - 2027
  • Figure-29: Disease wise - MMR Number (Million), 2016 - 2021
  • Figure-30: Disease wise - Forecast for MMR Number (Million), 2022 - 2027
  • Figure-31: Disease wise - Pneumococcal Number (Million), 2016 - 2021
  • Figure-32: Disease wise - Forecast for Pneumococcal Number (Million), 2022 - 2027
  • Figure-33: Disease wise - Meningococcal Number (Million), 2016 - 2021
  • Figure-34: Disease wise - Forecast for Meningococcal Number (Million), 2022 - 2027
  • Figure-35: Disease wise - Hepatitis Number (Million), 2016 - 2021
  • Figure-36: Disease wise - Forecast for Hepatitis Number (Million), 2022 - 2027
  • Figure-37: Disease wise - DTaP Number (Million), 2016 - 2021
  • Figure-38: Disease wise - Forecast for DTaP Number (Million), 2022 - 2027
  • Figure-39: Disease wise - Hib (Haemophilus Influenzae Type B) Number (Million), 2016 - 2021
  • Figure-40: Disease wise - Forecast for Hib (Haemophilus Influenzae Type B) Number (Million), 2022 - 2027
  • Figure-41: Disease wise - Combos (Combination Vaccines) Number (Million), 2016 - 2021
  • Figure-42: Disease wise - Forecast for Combos (Combination Vaccines) Number (Million), 2022 - 2027
  • Figure-43: Disease wise - Polio Number (Million), 2016 - 2021
  • Figure-44: Disease wise - Forecast for Polio Number (Million), 2022 - 2027
  • Figure-45: Disease wise - Rotavirus Number (Million), 2016 - 2021
  • Figure-46: Disease wise - Forecast for Rotavirus Number (Million), 2022 - 2027
  • Figure-47: Disease wise - Varicella Number (Million), 2016 - 2021
  • Figure-48: Disease wise - Forecast for Varicella Number (Million), 2022 - 2027
  • Figure-49: GlaxoSmithKline, plc.'s Vaccines Sales - Global Revenue (Million US$), 2016 - 2021
  • Figure-50: GlaxoSmithKline, plc.'s Vaccines Sales - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-51: Merck & Co. Vaccines Sales - Global Revenue (Million US$), 2016 - 2021
  • Figure-52: Merck & Co. Vaccines Sales - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-53: Sanofi Pasteur's Vaccines Sales - Global Revenue (Million US$), 2016 - 2021
  • Figure-54: Sanofi Pasteur's Vaccines Sales - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-55: Pfizer, Inc.'s Vaccines Sales - Global Revenue (Million US$), 2016 - 2021
  • Figure-56: Pfizer, Inc.'s Vaccines Sales - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-57: Thoracic Aortic Aneurysm (TAA)CSL Limited sales - Global Revenue (Million US$), 2016 - 2021
  • Figure-58: Thoracic Aortic Aneurysm (TAA)CSL Limited sales - Forecast for Global Revenue (Million US$), 2022 - 2027

List of Tables

  • Table-01: Global - Pediatric Vaccines Market Share (Percent), 2016 - 2021
  • Table-02: Global - Forecast for Pediatric Vaccines Market Share (Percent), 2022 - 2027
  • Table-03: Global - Pediatric Vaccines Population Share (Percent), 2016 - 2021
  • Table-04: Global - Forecast for Pediatric Vaccines Population Share (Percent), 2022 - 2027
目次

Global Pediatric Vaccines Market is expected to reach USD 62 Billion in 2027. In this huge market of vaccines Pediatric Vaccines for Coronavirus account for a significant market share. Over the years, Pediatric vaccination has made a tremendous public health success story. The lives of billions of children have been saved, and millions have the chance of a longer, healthier life, a more significant opportunity to learn, play, read and write, and move around freely without suffering. Besides, in the 21st century, the development, licensing, and implementation of Pediatric vaccines as part of large, systematic immunization programs have also addressed global health inequities. Therefore, imagining a world without vaccines would be life-threatening, with diseases presenting daily risk.

Impact of COVID-19 on Global Pediatric Vaccines Market

With the emergence of the SARS-CoV-2 virus in December 2019 and its potential for global dissemination to cause COVID-19 disease was realized, there was an urgent need to develop vaccines at an unprecedented rate and scale for the particular pandemic. Hence, amidst the pandemic, the global market for Pediatric vaccines declined in 2020 as most of the healthcares personal were busy in COVID-19 management.

However, the Pediatric vaccines market size has shown tremendous growth for the year 2021. All thanks to the COVID-19 vaccines approval for children in few western countries. Furthermore, as we appreciate and quantify the health, economic and social benefits of Pediatric vaccines and immunization programs to individuals and society. We endeavour to see the Global Pediatric Vaccine Industry to register a CAGR of 4.4% during the forecast period of 2021-2027.

Numbers of Vaccinated Pediatric (Infants) Remains Variable

At the same time, access to Pediatric vaccines that prevent life-threatening infectious diseases remains variable to all infants around the world. Further, to eradicate such problems, numerous individuals and agencies are working hard to address them globally. Recently, the development of safe and efficacious vaccination against diseases that cause substantial morbidity and mortality has been a significant scientific advance. Vaccination, sanitation, and clean drinking water are public health interventions that are undeniably responsible for improved infant health outcomes globally.

For instance, agencies including the United Nations Children's Fund (UNICEF), World Health Organization (WHO), Gavi, The Bill & Melinda Gates Foundation, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Initiative (CEPI), with their multiple funding streams have been instrumental in expanding vaccine benefits to all.

Worldwide Pediatric Vaccines Market Size was US$ 47.8 Billion for 2021

The global pediatric vaccines market is robust and has successfully reached enormous potential. Hence, pediatric vaccines are among tremendous advances in global health and development. Besides, pediatric vaccines have safely reduced the scourge of diseases like Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTaP, Hib (Haemophilus Influenza Type B), Combos (Combination Vaccines), Polio, Rotavirus and Varicella, helping children grow up healthy and happy. Remarkably, with immunization efforts worldwide, children can walk, play, dance and learn. Today, vaccines are expected to be one of the most cost-effective means of advancing global welfare.

Major Players in Global Pediatric Vaccines Market

The Pediatric vaccines market consists of several major players, including GlaxoSmithKline, Merck & Co, Sanofi Pasteur's, Pfizer, Inc. and Thoracic Aortic Aneurysm (TAA)CSL Limited. Notwithstanding, the key players of pediatric vaccines are broad and far-reaching, though not consistently quantifiable, analyzed or communicated. However, an increasing appreciation for vaccines' economic and social effects is being included in the development of the new vaccine, potentially realizing a more significant benefit to society and resulting in broader implementation by the companies.

Renub Research latest report "Pediatric Vaccines Market, Global Forecast By Disease Wise (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTaP, Hib (Haemophilus Influenza Type B), Combos (Combination Vaccines), Polio, Rotavirus and Varicella), Crop (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTaP, Hib (Haemophilus Influenza Type B), Combos (Combination Vaccines), Polio, Rotavirus and Varicella), Products and Pipeline (GSK Vaccine Product Pipeline, Merck Vaccine Product Pipeline, Sanofi Vaccine Product Pipeline and Pfizer Vaccine Product Pipeline), Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa), Key Players Sales (GlaxoSmithKline, Merck & Co, Sanofi Pasteur's, Pfizer, Inc. and Thoracic Aortic Aneurysm (TAA)CSL Limited)" provides a detailed analysis of Pediatric Vaccines Industry.

Disease wise - Pediatric (Infants) Vaccines Market have been covered from 12 viewpoints:

  • 1. Coronavirus (COVID-19)
  • 2. Influenza
  • 3. MMR (Measles, Mumps, and Rubella Vaccine)
  • 4. Pneumococcal
  • 5. Meningococcal
  • 6. Hepatitis
  • 7. DTaP
  • 8. Haemophilus Influenzae Type B (HIB)
  • 9. Combos (Combination)
  • 10. Polio
  • 11. Rotavirus
  • 12. Varicella

Disease wise - Numbers of Vaccinated Pediatric (Infants) have been covered from 12 viewpoints:

  • 1. Coronavirus (COVID-19)
  • 2. Influenza
  • 3. MMR (Measles, Mumps, and Rubella Vaccine)
  • 4. Pneumococcal
  • 5. Meningococcal
  • 6. Hepatitis
  • 7. DTaP
  • 8. Haemophilus Influenzae Type B (HIB)
  • 9. Combos (Combination)
  • 10. Polio
  • 11. Rotavirus
  • 12. Varicella

By Regions - Pediatric (Infants) Vaccines Market and Number have been covered from 5 viewpoints:

  • 1. North America
  • 2. Europe
  • 3. Asia Pacific
  • 4. Latin America
  • 5. Middle East and Africa

Vaccines - Products and Pipeline have been covered from 4 viewpoints:

  • 1. GSK Vaccine Product Pipeline
  • 2. Merck Vaccine Product Pipeline
  • 3. Sanofi Vaccine Product Pipeline
  • 4. Pfizer Vaccine Product Pipeline

Company Insight:

  • Overview
  • Recent Development
  • Sales Analysis

Vaccines Key Players Sales have been covered from 5 viewpoints:

  • 1. GlaxoSmithKline, Plc
  • 2. Merck & Co.
  • 3. Sanofi Pasteur's
  • 4. Pfizer, Inc.'s
  • 5. CSL Limited

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Driver
  • 4.2 Challenges

5. Pediatric (Infant) Vaccines Market

6. Pediatric Vaccinated Numbers

7. Market & Numbers Share - Pediatric Vaccine Analysis

  • 7.1 Pediatric Vaccine Market Share
  • 7.2 Pediatric Vaccinated Population Share
  • 7.3 By Regions Market share

8. Disease wise - Pediatric (Infants) Vaccines Market

  • 8.1 Influenza
  • 8.2 MMR (Measles, Mumps, and Rubella Vaccine)
  • 8.3 Pneumococcal
  • 8.4 Meningococcal
  • 8.5 Hepatitis
  • 8.6 DTaP
  • 8.7 Haemophilus Influenzae Type B (HIB)
  • 8.8 Combos (Combination)
  • 8.9 Polio
  • 8.10 Rotavirus
  • 8.11 Varicella

9. Disease wise - Numbers of Vaccinated Pediatric (Infants)

  • 9.1 Influenza
  • 9.2 MMR
  • 9.3 Pneumococcal
  • 9.4 Meningococcal
  • 9.5 Hepatitis
  • 9.6 DTaP
  • 9.7 Hib (Haemophilus Influenzae Type B)
  • 9.8 Combos (Combination Vaccines)
  • 9.9 Polio
  • 9.10 Rotavirus
  • 9.11 Varicella

10. By Region- Pediatric (Infants) Vaccines Market and Number

  • 10.1 North America
    • 10.1.1 Market
    • 10.1.2 Number
  • 10.2 Europe
    • 10.2.1 Market
    • 10.2.2 Number
  • 10.3 Asia Pacific
    • 10.3.1 Market
    • 10.3.2 Number
  • 10.4 Latin America
    • 10.4.1 Market
    • 10.4.2 Number
  • 10.5 Middle East and Africa
    • 10.5.1 Market
    • 10.5.2 Number

11. Mergers and Acquisitions in the Vaccine Industry

12. Vaccines and Regulator's Interventions

  • 12.1 Making and Meeting Standards of Quality and Safety
  • 12.2 Vaccine Funding

13. Vaccines - Products and Pipeline

  • 13.1 GSK Vaccine Product Pipeline
  • 13.2 Merck Vaccine Product Pipeline
  • 13.3 Sanofi Vaccine Product Pipeline
  • 13.4 Pfizer Vaccine Product Pipeline

14. Porters Five Forces

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15. Company Analysis

  • 15.1 GlaxoSmithKline, plc.
    • 15.1.1 Overview
    • 15.1.2 Recent Development
    • 15.1.3 Sales Analysis
  • 15.2 Merck & Co.
    • 15.2.1 Overview
    • 15.2.2 Recent Development
    • 15.2.3 Sales Analysis
  • 15.3 Sanofi Pasteur's
    • 15.3.1 Overview
    • 15.3.2 Recent Development
    • 15.3.3 Sales Analysis
  • 15.4 Pfizer, Inc.'s
    • 15.4.1 Overview
    • 15.4.2 Recent Development
    • 15.4.3 Sales Analysis
  • 15.5 CSL Limited
    • 15.5.1 Overview
    • 15.5.2 Recent Development
    • 15.5.3 Sales Analysis